Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Fate Therapeutics ( (FATE) ) has issued an announcement.
Fate Therapeutics announced the retirement of J. Scott Wolchko from his executive roles, effective December 31, 2024, and the appointment of Bahram Valamehr as his successor starting January 1, 2025. The company entered into a strategic advisory services agreement with Mr. Wolchko, allowing him to provide advisory services throughout 2025 with compensations and continued vesting of his equity awards, ensuring a smooth transition and maintaining continuity in leadership.
More about Fate Therapeutics
Fate Therapeutics is a company involved in the biotechnology industry, focusing on the development of cellular immunotherapies for cancer and immune disorders.
YTD Price Performance: 0.56%
Average Trading Volume: 2,961,505
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $205M
For a thorough assessment of FATE stock, go to TipRanks’ Stock Analysis page.
